Quarterly Financial Performance – Q2 FY22 vs Q2 FY21

For the second quarter ended 30th September 2021, the company recorded revenue of Rs  593 crore as compared to Rs 444 crore, registering a growth of 34% over the corresponding quarter ended 30th September 2020. Operating EBITDA increased by 27% to Rs 140 crore as compared to Rs 110 crores. Adjusted EBITDA increased by 40 % to Rs 154 crores. Profit after Tax stood at Rs 98 crores as compared to Rs 74 crores registering growth of 32%.

Commenting on financial results, Nikhil Chopra, CEO and Wholetime Director, JBCPL said, “Our strong operational performance has led to market-beating growth in India and steady performance in international business despite pandemic related issues and supply chain uncertainties.” He further added “During the past one year, several initiatives including the re-aligned Go-To-Market model, diversification into complementary therapies and new launches have helped us sustain our growth momentum in India leading to market share gains and rank improvement. While international business is confronted with external market challenges, our key markets like South Africa and the US have done well and Russia is showing signs of steady revival. We are working aggressively on expanding our offerings in the international market by reorienting our R&D and aggressively pursuing business development opportunities. Going forward, our priority will be to further optimize our cost structure and continue to build on the revenue momentum in line with our strategic priorities.

Financial Performance – H1 FY22 vs H1 FY21

 For the first half of the financial year 2021-22, the company recorded revenue of Rs 1,199 crore as compared to Rs 966 crores, registering a growth of 24% over the corresponding period ended 30th September 2020. Operating EBITDA increased by 14% to Rs 303 crore as compared to Rs 266 crore. Adjusted EBITDA increased by 19.2% to Rs 317 crore. Profit after Tax stood at Rs 217 crore as compared to Rs 193 crores registering a growth of 12%.